BioXcel Therapeutics (BTAI) Tops Q3 EPS by 19c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($0.32), $0.19 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance